PL343705A1 - Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine - Google Patents

Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine

Info

Publication number
PL343705A1
PL343705A1 PL99343705A PL34370599A PL343705A1 PL 343705 A1 PL343705 A1 PL 343705A1 PL 99343705 A PL99343705 A PL 99343705A PL 34370599 A PL34370599 A PL 34370599A PL 343705 A1 PL343705 A1 PL 343705A1
Authority
PL
Poland
Prior art keywords
chloronaphth
4pyridyl
ylsulphonyl
piperazine
benzoyl
Prior art date
Application number
PL99343705A
Other languages
English (en)
Inventor
Marianne Ashford
Roger James
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL343705A1 publication Critical patent/PL343705A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL99343705A 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine PL343705A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9809350.3A GB9809350D0 (en) 1998-05-02 1998-05-02 Novel salt

Publications (1)

Publication Number Publication Date
PL343705A1 true PL343705A1 (en) 2001-08-27

Family

ID=10831311

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99343705A PL343705A1 (en) 1998-05-02 1999-04-27 Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine

Country Status (16)

Country Link
EP (1) EP1084118A1 (xx)
JP (1) JP2002513789A (xx)
KR (1) KR20010043216A (xx)
CN (1) CN1308629A (xx)
AU (1) AU3719699A (xx)
BR (1) BR9910176A (xx)
CA (1) CA2331041A1 (xx)
EE (1) EE200000638A (xx)
GB (1) GB9809350D0 (xx)
HU (1) HUP0102394A3 (xx)
IL (1) IL139405A0 (xx)
NO (1) NO20005498D0 (xx)
PL (1) PL343705A1 (xx)
SK (1) SK16522000A3 (xx)
WO (1) WO1999057112A1 (xx)
ZA (1) ZA200006036B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833036T2 (de) * 1997-09-30 2006-06-22 Daiichi Pharmaceutical Co., Ltd. Sulfonylderivate
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
ATE334975T1 (de) * 1997-05-30 2006-08-15 Takeda Pharmaceutical Sulfonamidderivate, ihre herstellung und verwendung
DE69833036T2 (de) * 1997-09-30 2006-06-22 Daiichi Pharmaceutical Co., Ltd. Sulfonylderivate

Also Published As

Publication number Publication date
SK16522000A3 (sk) 2001-05-10
WO1999057112A1 (en) 1999-11-11
EE200000638A (et) 2002-04-15
HUP0102394A2 (hu) 2001-12-28
HUP0102394A3 (en) 2003-01-28
ZA200006036B (en) 2002-01-25
IL139405A0 (en) 2001-11-25
NO20005498L (no) 2000-11-01
JP2002513789A (ja) 2002-05-14
BR9910176A (pt) 2001-01-09
GB9809350D0 (en) 1998-07-01
NO20005498D0 (no) 2000-11-01
CN1308629A (zh) 2001-08-15
CA2331041A1 (en) 1999-11-11
EP1084118A1 (en) 2001-03-21
KR20010043216A (ko) 2001-05-25
AU3719699A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
PL347635A1 (en) New piperazine and piperidine compounds
IL146707A0 (en) Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts
AU4994693A (en) 4-{2-(4-(2-pyridinyloxy)phenyl)ethoxy}-quinazoline and analogues thereof
IL126295A0 (en) New piperazine and piperidine compounds
NZ325845A (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives, preparation and pharmaceutical use thereof
IL152177A0 (en) Piperazine and piperidine compounds
EE200100498A (et) 1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine
NZ299788A (en) 4-substituted(4-(1-adamantyl)phenyl) derivatives
DE69629454D1 (en) Antipsychotische 4-(1h-indolyl-1-yl)-1-substituierte piperidine derivate
IL121461A0 (en) Use of 1-[4-[4-aryl (or heteroaryl)-1-piperazinyl]butyl]-1H-azole derivatives
PL343705A1 (en) Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl] piperazine
AU7578296A (en) Piperazine, piperidine and tetrahydropyridine derivatives
EP1071156A3 (en) In-band-flat-group-delay type dielectric filter and linearized amplifier using the same
AU3168997A (en) 1-(1h-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor
HUP9800511A3 (en) Phosphorylized derivatives of 4-{4-[4-(hydroxy-diphenyl)-1-pipe
AU699606B2 (en) Antidepressant 1-arylalkyl-4-(alkoxypyridinyl)- or 4-(alkoxypyrimidinyl) piperazine derivatives
IL143779A0 (en) Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
NZ306319A (en) 1-alkylphenyl substituted 4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butanol derivatives and medicaments
AU6487294A (en) Piperidines and piperazines
JPS6447776A (en) 1-(2-(phenylmethyl)phenyl)piperazine compound, manufacture and medicinal composition
ZA958532B (en) Compounds having a 1-(arylalkenyl)-4-(arylmethyl)piperazine structure process and preparing them and pharmaceutical compositions containing them
AU6705396A (en) 1-(2-(2,3-Dihydro-1H-inden-1-yl)ethyl)-4-(naphthalen-1-YL) piperazine derivatives, their preparation and their application in therapeutics
AU2003200717B8 (en) Cyclin-dependent kinase inhibitors and uses thereof
GB9610093D0 (en) (-)-(3R)-methyl-4-[4-[4-(4-pyridyl) piperazin-1-yl] phenoxy] butyric acid
AU2003200717A1 (en) Cyclin-dependent kinase inhibitors and uses thereof

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)